63.4
Elena Diez‐Cecilia
University Health Network, Krembil Research Institute
Elena Diez-Cecilia has made significant contributions to the understanding of Alzheimer's disease, proposing a dual-action therapeutic platform that targets both immunopathic and proteopathic mechanisms. By inhibiting indoleamine 2,3-dioxygenase-mediated tryptophan metabolism and β-amyloid aggregation, their work suggests that AD may be an autoimmune disorder modulated by endogenous tryptophan metabolites. Additionally, research on artificial intelligence for COVID-19 drug discovery and vaccine development highlights the potential of AI in accelerating pandemic response efforts. Diez-Cecilia's findings also reveal the efficacy of novel compounds against protein misfolding and oligomerization of beta-amyloid, as well as their application as kinase inhibitors, with implications for various diseases beyond AD.